Inactivation of antiviral defenses such as type I interferon (IFN) responses in many cancer cells, viral deletions allowing replication only in tumor cells that can substitute for viral defects, tumor-selective uptake via upregulated or mutated receptors, and targeting to tumor promoters are all considered for tumor specificity. The gene discussed is IFNA1; the disease is neoplasm.